



## ASX ANNOUNCEMENT

23 FEBRUARY 2022

### **HITIQ Awarded Second Australian Innovation Patent For New Heart Rate Monitoring Functionality Within The Mouthguard**

- > **HITIQ secures its second, consecutive Australian Innovation Patent as part of its product technology extension strategy;**
- > **Patent awarded for HITIQ's smart mouthguard with new heart rate monitoring functionality; and**
- > **Provides protection for planned future technology generations as the Company builds its eco-system of products for the world's first end to-end concussion management platform.**

**Transformative, concussion management technology company, HITIQ Limited (ASX: HIQ) (HITIQ or the Company),** is pleased to announce that it has secured a second Australian Innovation Patent for new functionality associated with its smart mouthguard technology.

#### **AUSTRALIAN INNOVATION PATENT**

An Australian Innovation Patent (Patent No. 2021107530) has been awarded to HITIQ for "A Protective Mouthguard Device Configured To Enable Measurement Of Circulatory System Parameters". Key features of this patent cover the use of light emitting and light sensor components in a protective mouthguard that enable measurement of the wearer's physiological condition. These include:

- One or more light emitting components emit light at a controlled wavelength into the wearer's bodily tissue;
- One or more light sensor components sense the light, as affected by interaction with the bodily tissue; and
- Data is processed to generate metrics representative of physiological condition (for example heart rate).

#### **PLATFORM AND PRODUCT TECHNOLOGY EXTENSION**

This new biometric tracking functionality and the associated IP protection is part of HITIQ's continued technology innovation and eco-system development, targeting a leadership position in concussion healthcare and mouthguard technology.

HITIQ plans to incorporate this technology extension into future generations of its smart mouthguard to deliver a sophisticated and improved analysis of athletic performance, including the potential effects of head impacts on other bodily systems.

#### **HITIQ Limited**

ACN 609 543 213  
ASX: HIQ

**HITIQ.COM**

#### **Corporate Office**

Level 2, 9-17 Raglan Street  
South Melbourne VIC 3205

E: [investors@hitiq.com](mailto:investors@hitiq.com)

#### **Directors**

Otto Buttula	Non-Executive Chair
Michael Vegar	Managing Director
Phillip Carulli	Non-Executive Director
Glenn Smith	Non-Executive Director
Aidan Clarke	Non-Executive Director

**Commenting on the new product functionality developed and IP protection, HITIQ CEO, Mike Vegar, added:**

- : *“This is a valuable product enhancement for our customers that will ultimately make its way into future*
- releases of HITIQ concussion management technology. Data and innovation is at the core of the*
- Company’s focus to transform the concussion healthcare space, so I am pleased that we are able to evolve*
- quickly whilst protecting our first mover advantage.*
- :
- : *The team is currently working through our product development protocols which will determine when the*
- new functionality may be made available to new and existing customers.”*

**- ENDS -**

Authorised for release by the Board of Directors.

**For more information, contact:**

Mike Vegar	Elvis Jurcevic
<b>CEO &amp; MD</b>	<b>Investor Relations</b>
HITIQ Limited	+61 408 268 271
investors@hitiq.com	ej@hitiq.com

**About HITIQ**

HITIQ Limited (ASX: **HIQ**) operates in the healthcare equipment sector, providing and further developing a transformative, end-to-end concussion management technology platform. This platform aims to provide a total concussion ecosystem whereby the Company’s products support the identification, monitoring and management of sport related brain injury. HITIQ’s product suite utilises high-end technology that will span multiple domains – from early detection and surveillance to assessment and rehabilitation technology tools.

HITIQ is targeting a growing worldwide concussion management market including elite and recreational sport, clinical practitioners, military, research, and combat sports. The Company’s first commercial partner is the Australian Football League, with current strategy initiatives expanding commercially into Rugby League, Rugby Union, Ice Hockey, Lacrosse, MMA and American Football (particularly the NCAA). The market opportunity globally represents ~500k athletes within the elite market and ~10million in the consumer market.